SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML ...

— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the successful completion of ...

— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study ...

Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with ...

OncotoX-AML is an engineered biologic designed to selectively kill both AML blasts (abnormal myeloid cells) and relapse-related leukemia stem cells. Its unique mechanism of action is independent of ...

More than five years ago, Congress passed a comprehensive anti-money-laundering and countering the financing of terrorism, or AML/CFT, reform law. The future looked bright, heralding the prospect of ...